A Study of Combination Thalidomide Plus Dexamethasone Therapy vs. Dexamethasone Therapy Alone in Previously Untreated Subjects With Multiple Myeloma
To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma
Multiple Myeloma
DRUG: A (Thalidomide + Dexamethasone)|DRUG: B (Placebo + Dexamethasone)
Time to tumor progression (TTP), Time to tumor progression (TTP), Up to 3 years
Number of patients who survived, Number of patients who survived, Up to 3 years|Time to first symptomatic skeletal-related event (SRE)(clinical need for radiation therapy or surgery to bone), Time to first symptomatic skeletal-related event (SRE)(clinical need for radiation therapy or surgery to bone), Up to 3 years|Myeloma response rate, Myeloma response determination criteria developed by Blad√© et al 1998, Up to 3 years|Number of participants with adverse events, Number of participants with adverse events, Up to 3 years
To compare the efficacy of combination oral thalidomide plus oral dexamethasone treatment to that of oral dexamethasone-alone treatments as induction (first-line) therapy for subjects with active multiple myeloma